-
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesSD Wiviott，I Raz，DECLARE–TIMI 58 Investigators. -
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HFMartinez FA, Serenelli M, Nicolau JC et al.
-
SPECT and PET in ischemic heart failureAngelidis G, Giamouzis G, Karagiannis G et al.
-
The pyruvate-lactate axis modulates cardiac hypertrophy and heart failureAA Cluntun, R Badolia, SG Drakos et al.
-
Association Between Functional Impairment and Medication Burden in Adults with Heart FailureGoyal P, Bryan J, Kneifati-Hayek J et al.
-
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionSD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,
-
Association of Cardiovascular Disease With Respiratory DiseaseP Carter, J Lagan, C Fortune et al.
-
Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart FailureDM Cibi, KW Bi-Lin, MK Singh et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
